Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Berk, MD
Arcutis Biotherapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
76 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Arcutis Clinical Site 29
Calgary, Alberta, Canada
- Arcutis Clinical Site 64
Winnipeg, Manitoba, Canada
- Arcutis Clinical Site 73
Burlington, Ontario, Canada
- Arcutis Clinical Site 36
Markham, Ontario, Canada
- Arcutis Clinical Site 78
Saskatoon, Saskatchewan, Canada
- Arcutis Clinical Site 14
Birmingham, Alabama, United States
- Arcutis Clinical Site 56
Birmingham, Alabama, United States
- Arcutis Clinical Site 69
Montgomery, Alabama, United States
- Arcutis Clinical Site 68
Gilbert, Arizona, United States
- Arcutis Clinical Site 26
Scottsdale, Arizona, United States
- Arcutis Clinical Site 50
Bryant, Arkansas, United States
- Arcutis Clinical Site 59
Fort Smith, Arkansas, United States
- Arcutis Clinical Site 71
Little Rock, Arkansas, United States
- Arcutis Clinical Site 09
Inglewood, California, United States
- Arcutis Clinical Site 45
Rancho Santa Margarita, California, United States
- Arcutis Clinical Site 30
San Diego, California, United States
- Arcutis Clinical Site 70
Thousand Oaks, California, United States
- Arcutis Clinical Site 48
Boca Raton, Florida, United States
- Arcutis Clinical Site 12
Coral Gables, Florida, United States
- Arcutis Clinical Site 33
Coral Gables, Florida, United States
- Arcutis Clinical Site 11
Delray Beach, Florida, United States
- Arcutis Clinical Site 28
Largo, Florida, United States
- Arcutis Clinical Site 43
Miami, Florida, United States
- Arcutis Clinical Site 79
Miami, Florida, United States
- Arcutis Clinical Site 10
Miami Lakes, Florida, United States
- Arcutis Clinical Site 35
North Miami Beach, Florida, United States
- Arcutis Clinical Site 75
Wellington, Florida, United States
- Arcutis Clinical Site 20
Sandy Springs, Georgia, United States
- Arcutis Clinical Site 82
Boise, Idaho, United States
- Arcutis Clinical Site 60
Chicago, Illinois, United States
- Arcutis Clinical Site 07
Rolling Meadows, Illinois, United States
- Arcutis Clinical Site 42
Clarksville, Indiana, United States
- Arcutis Clinical Site 21
Plainfield, Indiana, United States
- Arcutis Clinical Site 57
West Lafayette, Indiana, United States
- Arcutis Clinical Site 22
Louisville, Kentucky, United States
- Arcutis Clinical Site 46
Louisville, Kentucky, United States
- Arcutis Clinical Site 84
Baton Rouge, Louisiana, United States
- Arcutis Clinical Site 34
Lake Charles, Louisiana, United States
- Arcutis Clinical Site 40
Metairie, Louisiana, United States
- Arcutis Clinical Site 51
Metairie, Louisiana, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Apr 2021
- Primary completion
- 1 Jun 2023
- Completion
- 1 Jun 2023
- Last update posted
- 23 Dec 2025
- Registered enrollment
- 652
- Registry id
- NCT04845620
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.